Legal & General Group PLC Vertex Pharmaceuticals Inc Transaction History

Legal & General Group PLC

$420 Billion
Q1 2024

A detailed history of Legal & General Group PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 2,393,573 shares of VRTX stock, worth $1.09 Billion. This represents 0.24% of its overall portfolio holdings.

Number of Shares

2,393,573

Previous 2,430,665 1.53%

Holding current value

$1.09 Billion

Previous $989 Million 1.17%

% of portfolio

0.24%

Previous 0.26%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $15.1 Million - $16.5 Million	-37,092 Reduced 1.53%	2,393,573 $1 Billion
Q4 2023 Feb 15, 2024	BUY	$343.0 - $410.68 $134 Million - $160 Million	390,307 Added 19.13%	2,430,665 $989 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $29.9 Million - $32.1 Million	-88,561 Reduced 4.16%	2,040,358 $710 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $13.4 Million - $15 Million	42,588 Added 2.04%	2,128,919 $749 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $15 Million - $17.1 Million	52,967 Added 2.6%	2,086,331 $657 Million

Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $29.9 Million - $33.7 Million	-104,734 Reduced 4.9%	2,033,364 $587 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $17.2 Million - $19.1 Million	-62,651 Reduced 2.85%	2,138,098 $619 Million
Q2 2022 Aug 22, 2022	BUY	$234.96 - $292.55 $33.7 Million - $42 Million	143,620 Added 6.98%	2,200,749 $620 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $35.1 Million - $41.4 Million	158,485 Added 8.35%	2,057,129 $537 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $30 Million - $37.9 Million	-169,690 Reduced 8.2%	1,898,644 $417 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $21.6 Million - $24.2 Million	119,277 Added 6.12%	2,068,334 $375 Million
Q2 2021 Aug 12, 2021	BUY	$187.49 - $221.1 $45.1 Million - $53.2 Million	240,660 Added 14.09%	1,949,057 $393 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $2.47 Million - $2.88 Million	-11,931 Reduced 0.69%	1,708,397 $367 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $7.13 Million - $9.5 Million	34,424 Added 2.04%	1,720,328 $407 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $12.1 Million - $14.3 Million	47,162 Added 2.88%	1,685,904 $459 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $12.2 Million - $16 Million	53,940 Added 3.4%	1,638,742 $476 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $13.3 Million - $16.5 Million	66,406 Added 4.37%	1,584,802 $377 Million
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $9.25 Million - $12.4 Million	55,481 Added 3.79%	1,518,396 $332 Million
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $548,060 - $616,835	3,297 Added 0.23%	1,462,915 $248 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $1.37 Million - $1.58 Million	8,308 Added 0.57%	1,459,618 $268 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $48.7 Million - $58 Million	297,731 Added 25.81%	1,451,310 $267 Million
Q4 2018 Feb 15, 2019	BUY	$151.91 - $192.21 $12 Million - $15.2 Million	79,216 Added 7.37%	1,153,579 $191 Million
Q3 2018 Nov 20, 2018	BUY	$167.73 - $192.74 $3.46 Million - $3.98 Million	20,630 Added 1.96%	1,074,363 $207 Million
Q2 2018 Aug 10, 2018	SELL	$145.72 - $169.96 $6.33 Million - $7.38 Million	-43,434 Reduced 3.96%	1,053,733 $179 Million
Q1 2018 May 17, 2018	SELL	$151.6 - $177.13 $8.17 Million - $9.55 Million	-53,915 Reduced 4.68%	1,097,167 $179 Million
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $158 Million - $179 Million	1,151,082	1,151,082 $173 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Vertex Pharmaceuticals Inc Transaction History